Primary biliary cirrhosis: A multi-faced interactive disease involving genetics, environment and the immune response

APMIS

Volumn 120, Issue 11, 2012, Pages 857-871

  Uibo, Raivo ^a,b   Kisand, Kai ^a   Yang, Chen Yen ^c   Gershwin, M Eric ^c  

^a Faculty of Medicine   (Estonia)

^b ESTONIAN ACADEMY OF SCIENCES   (Estonia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibodies; Autoantigens; Etiology; Genes; Innate immunity; Microorganisms; Primary biliary cirrhosis; Xenobiotics

Indexed keywords

AUTOANTIBODY; XENOBIOTIC AGENT;

ALLELE; ARTICLE; AUTOIMMUNITY; ENVIRONMENT; ENVIRONMENTAL FACTOR; EPIGENETICS; ESCHERICHIA COLI; GENETICS; HELICOBACTER; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MYCOBACTERIUM; NONHUMAN; PATHOLOGY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; X CHROMOSOME; Y CHROMOSOME;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; BILE DUCTS, INTRAHEPATIC; DISEASE MODELS, ANIMAL; ENVIRONMENT; EPIGENESIS, GENETIC; EPITHELIUM; HUMANS; IMMUNITY, INNATE; LIVER CIRRHOSIS, BILIARY; MITOCHONDRIA; T-LYMPHOCYTES;

EID: 84866841718     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2012.02914.x     Document Type: Article

References (143)

1. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet 2011;377:1600-9.
2. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978;379:103-12.
3. Scheuer PJ. Primary biliary cirrhosis: diagnosis, pathology and pathogenesis. Postgrad Medical J 1983;59(Suppl 4):106-15.
4. Garrido MC, Hubscher SG. Accuracy of staging in primary biliary cirrhosis. J Clin Pathol 1996;49:556-9.
5. Nakanuma Y, Zen Y, Harada K, Sasaki M, Nonomura A, Uehara T, et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement. Pathol Int 2010;60:167-74.
6. Hayday A, Theodoridis E, Ramsburg E, Shires J. Intraepithelial lymphocytes: exploring the Third Way in immunology. Nat Immunol 2001;2:997-1003.
7. Heathcote EJ. Primary biliary cirrhosis: historical perspective. Clin Liver Dis 2003;7:735-40.
8. Walker JG, Doniach D, Roitt IM, Sherlock S. Serological tests in diagnosis of primary biliary cirrhosis. Lancet 1965;1:827-31.
9. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012;56:1181-8.
10. Uibo R, Salupere V. The epidemiology of primary biliary cirrhosis: immunological problems. Hepatogastroenterology 1999;46:3048-52.
11. Kisand KE, Metskula K, Kisand KV, Kivik T, Gershwin ME, Uibo R. The follow-up of asymptomatic persons with antibodies to pyruvate dehydrogenase in adult population samples. J Gastroenterol 2001;36:248-54.
12. Turchany JM, Uibo R, Kivik T, Van de Water J, Prindiville T, Coppel RL, et al. A study of antimitochondrial antibodies in a random population in Estonia. Am J Gastroenterol 1997;92:124-6.
13. Smyk D, Mytilinaiou MG, Rigopoulou EI, Bogdanos DP. PBC triggers in water reservoirs, coal mining areas and waste disposal sites: from Newcastle to New York. Dis Markers 2010;29:337-44.
14. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010;34:J258-65.
15. Berkun Y, Padeh S. Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev 2010;9:A319-24.
16. Bhat A, Naguwa S, Cheema G, Gershwin ME. The epidemiology of transverse myelitis. Autoimmun Rev 2010;9:A395-9.
17. Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010;9:A299-304.
18. Borchers AT, Naguwa SM, Keen CL, Gershwin ME. The implications of autoimmunity and pregnancy. J Autoimmun 2010;34:J287-99.
19. Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010;9:A277-87.
20. Borchers AT, Uibo R, Gershwin ME. The geoepidemiology of type 1 diabetes. Autoimmun Rev 2010;9:A355-65.
21. Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y. Epigenetics and autoimmunity. J Autoimmun 2010;34:J207-19.
22. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010;34:J314-21.
23. Chang C. The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 2010;34:J234-46.
24. Chang C, Gershwin ME. Drugs and autoimmunity-a contemporary review and mechanistic approach. J Autoimmun 2010;34:J266-75.
25. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun 2010;34:J276-86.
26. Chen M, Kallenberg CG. The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 2010;9:A293-8.
27. Deane S, Teuber SS, Gershwin ME. The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev 2010;9:A342-9.
28. Ehrenfeld M. Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 2010;9:A325-9.
29. Hemminki K, Li X, Sundquist J, Sundquist K. The epidemiology of Graves' disease: evidence of a genetic and an environmental contribution. J Autoimmun 2010;34:J307-13.
30. Hershko AY, Naparstek Y. Autoimmunity in the era of genomics and proteomics. Autoimmun Rev 2006;5:230-3.
31. Hoffmann MH, Trembleau S, Muller S, Steiner G. Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 2010;34:J178-206.
32. Invernizzi P. Geoepidemiology of autoimmune liver diseases. J Autoimmun 2010;34:J300-6.
33. Lambert JF, Nydegger UE. Geoepidemiology of autoimmune hemolytic anemia. Autoimmun Rev 2010;9:A350-4.
34. Leung PS, Shu SA, Kenny TP, Wu PY, Tao MH. Development and validation of gene therapies in autoimmune diseases: epidemiology to animal models. Autoimmun Rev 2010;9:A400-5.
35. Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME. Definition of human autoimmunity - autoantibodies versus autoimmune disease. Autoimmun Rev 2010;9:A259-66.
36. Logan I, Bowlus CL. The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 2010;9:A372-8.
37. Mackay IR. Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev 2010;9:A251-8.
38. Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H. Light, including ultraviolet. J Autoimmun 2010;34:J247-57.
39. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjogren's syndrome. Autoimmun Rev 2010;9:A305-10.
40. Meyer A, Levy Y. Chapter 33: geoepidemiology of myasthenia gravis. Autoimmun Rev 2010;9:A383-6.
41. Meyer N, Misery L. Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 2010;9:A379-82.
42. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010;9:A387-94.
43. Powell JJ, Faria N, Thomas-McKay E, Pele LC. Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 2010;34:J226-33.
44. Prieto S, Grau JM. The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 2010;9:A330-4.
45. Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010;9:A311-8.
46. Round JL, O'Connell RM, Mazmanian SK. Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 2010;34:J220-5.
47. Rubtsov AV, Rubtsova K, Kappler JW, Marrack P. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev 2010;9:494-8.
48. Sands J, Tuscano JM. Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 2010;9:A335-41.
49. Segelmark M, Hellmark T. Autoimmune kidney diseases. Autoimmun Rev 2010;9:A366-71.
50. Selmi C. The worldwide gradient of autoimmune conditions. Autoimmun Rev 2010;9:A247-50.
51. Selmi C, Tsuneyama K. Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 2010;9:A267-70.
52. Shapira Y, Agmon-Levin N, Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 2010;34:J168-77.
53. Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 2008;31:325-30.
54. Stojanovich L. Stress and autoimmunity. Autoimmun Rev 2010;9:A271-6.
55. Tobon GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 2010;9:A288-92.
56. Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun 2010;34:J322-6.
57. Tonutti E, Visentini D, Bizzaro N. Interpretative comments on autoantibody tests. Autoimmun Rev 2007;6:341-6.
58. Youinou P, Pers JO, Gershwin ME, Shoenfeld Y. Geo-epidemiology and autoimmunity. J Autoimmun 2010;34:J163-7.
59. Zeki AA, Schivo M, Chan AL, Hardin KA, Kenyon NJ, Albertson TE, et al. Geoepidemiology of COPD and idiopathic pulmonary fibrosis. J Autoimmun 2010;34:J327-38.
60. Invernizzi P, Miozzo M, Battezzati PM, Bianchi I, Grati FR, Simoni G, et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004;363:533-5.
61. Miozzo M, Selmi C, Gentilin B, Grati FR, Sirchia S, Oertelt S, et al. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology 2007;46:456-62.
62. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005;42:1194-202.
63. Parikh-Patel A, Gold E, Mackay IR, Gershwin ME. The geoepidemiology of primary biliary cirrhosis: contrasts and comparisons with the spectrum of autoimmune diseases. Clin Immunol 1999;91:206-18.
64. Lazaridis KN, Talwalkar JA. Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol 2007;41:494-500.
65. Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 2004;127:485-92.
66. Abu-Mouch S, Selmi C, Benson GD, Kenny TP, Invernizzi P, Zuin M, et al. Geographic clusters of primary biliary cirrhosis. Clin Dev Immunol 2003;10:127-31.
67. Hirschfield GM, Invernizzi P. Progress in the genetics of primary biliary cirrhosis. Semin Liver Dis 2011;31:147-56.
68. Gordon MA, Oppenheim E, Camp NJ, di Giovine FS, Duff GW, Gleeson D. Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region. J Hepatol 1999;31:242-7.
69. Poupon R, Ping C, Chretien Y, Corpechot C, Chazouilleres O, Simon T, et al. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol 2008;49:1038-45.
70. Miyake Y, Ikeda F, Takaki A, Nouso K, Yamamoto K. +49A/G polymorphism of cytotoxic T-lymphocyte antigen 4 gene in type 1 autoimmune hepatitis and primary biliary cirrhosis: A meta-analysis. Hepatol Res 2011;41:151-9.
71. Li X, Zhang C, Zhang J, Zhang Y, Wu Z, Yang L, et al. Polymorphisms in the CTLA-4 gene and rheumatoid arthritis susceptibility: a meta-analysis. J Clin Immunol 2012;doi: 10.1007/s10875-012-9650-y.
72. Juran BD, Atkinson EJ, Schlicht EM, Fridley BL, Lazaridis KN. Primary biliary cirrhosis is associated with a genetic variant in the 3′ flanking region of the CTLA4 gene. Gastroenterology 2008;135:1200-6.
73. Juran BD, Atkinson EJ, Larson JJ, Schlicht EM, Liu X, Heathcote EJ, et al. Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction. Hepatology 2010;52:223-9.
74. Kavvoura FK, Ioannidis JP. CTLA-4 gene polymorphisms and susceptibility to type 1 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol 2005;162:3-16.
75. Kavvoura FK, Akamizu T, Awata T, Ban Y, Chistiakov DA, Frydecka I, et al. Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis. J Clin Endocrinol Metab 2007;92:3162-70.
76. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev 2011;241:180-205.
77. Kimura Y, Selmi C, Leung PS, Mao TK, Schauer J, Watnik M, et al. Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis. Hepatology 2005;41:55-63.
78. Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009;360:2544-55.
79. Liu X, Invernizzi P, Lu Y, Kosoy R, Lu Y, Bianchi I, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 2010;42:658-60.
80. Tanaka A, Invernizzi P, Ohira H, Kikuchi K, Nezu S, Kosoy R, et al. Replicated association of 17q12-21 with susceptibility of primary biliary cirrhosis in a Japanese cohort. Tissue Antigens 2011;78:65-8.
81. Hirschfield GM, Xie G, Lu E, Sun Y, Juran BD, Chellappa V, et al. Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes Immun 2012;doi: 10.1038/gene.2011.89.
82. Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 2011;43:329-32.
83. Baum H. Mitochondrial antigens, molecular mimicry and autoimmune disease. Biochim Biophys Acta 1995;1271:111-21.
84. Burroughs AK, Butler P, Sternberg MJ, Baum H. Molecular mimicry in liver disease. Nature 1992;358:377-8.
85. Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med 1995;181:1835-45.
86. Murakami K, Takahashi R, Ono M, Watanabe K, Okimoto T, Kodama M, et al. Serodiagnosis of Helicobacter hepaticus infection in patients with liver and gastrointestinal diseases: western blot analysis and ELISA using a highly specific monoclonal antibody for H. hepaticus antigen. J Gastroenterol 2011;46:1120-6.
87. Vorobjova T, Nilsson I, Terjajev S, Granholm M, Lyyra M, Porkka T, et al. Serum antibodies to enterohepatic Helicobacter spp. in patients with chronic liver diseases and in a population with high prevalence of H. pylori infection. Dig Liver Dis 2006;38:171-6.
88. Nilsson HO, Taneera J, Castedal M, Glatz E, Olsson R, Wadstrom T. Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. J Clin Microbiol 2000;38:1072-6.
89. Vilagut L, Vila J, Vinas O, Pares A, Gines A, Jimenez de Anta MT, et al. Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. J Hepatol 1994;21:673-7.
90. Bogdanos DP, Baum H, Okamoto M, Montalto P, Sharma UC, Rigopoulou EI, et al. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology 2005;42:458-65.
91. Kranich J, Maslowski KM, Mackay CR. Commensal flora and the regulation of inflammatory and autoimmune responses. Semin Immunol 2011;23:139-45.
92. Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003;38:1250-7.
93. Mattner J, Savage PB, Leung P, Oertelt SS, Wang V, Trivedi O, et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 2008;3:304-15.
94. Mohammed JP, Fusakio ME, Rainbow DB, Moule C, Fraser HI, Clark J, et al. Identification of Cd101 as a susceptibility gene for Novosphingobium aromaticivorans-induced liver autoimmunity. J Immunol 2011;187:337-49.
95. Leung PS, Park O, Tsuneyama K, Kurth MJ, Lam KS, Ansari AA, et al. Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization. J Immunol 2007;179:2651-7.
96. Leung PS, Quan C, Park O, Van de Water J, Kurth MJ, Nantz MH, et al. Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies. J Immunol 2003;170:5326-32.
97. Wakabayashi K, Yoshida K, Leung PS, Moritoki Y, Yang GX, Tsuneyama K, et al. Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. Clin Exp Immunol 2009;155:577-86.
98. Amano K, Leung PS, Rieger R, Quan C, Wang X, Marik J, et al. Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol 2005;174:5874-83.
99. Stockinger B, Hirota K, Duarte J, Veldhoen M. External influences on the immune system via activation of the aryl hydrocarbon receptor. Semin Immunol 2011;23:99-105.
100. Mitchell MM, Lleo A, Zammataro L, Mayo MJ, Invernizzi P, Bach N, et al. Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. Epigenetics 2011;6:95-102.
101. Lleo A, Liao J, Invernizzi P, Zhao M, Bernuzzi F, Ma L, et al. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology 2012;55:153-60.
102. Mackay IR. Primary biliary cirrhosis showing a high titer of autoantibody; report of a case. N Engl J Med 1958;258:185-8.
103. Kisand K, Boe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010;207:299-308.
104. Meager A, Visvalingam K, Peterson P, Moll K, Murumagi A, Krohn K, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 2006;3:e289.
105. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987;138:3525-31.
106. Ishibashi H, Shimoda S, Gershwin ME. The immune response to mitochondrial autoantigens. Semin Liver Dis 2005;25:337-46.
107. Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997;25:1090-5.
108. Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watson AJ, et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 1986;6:1279-84.
109. Uibo R, Mackay IR, Rowley M, Humphries P, Armstrong JM, McNeilage J. Inhibition of enzyme function by human autoantibodies to an autoantigen pyruvate dehydrogenase E2: different epitope for spontaneous human and induced rabbit autoantibodies. Clin Exp Immunol 1990;80:19-24.
110. Bruggraber SF, Leung PS, Amano K, Quan C, Kurth MJ, Nantz MH, et al. Autoreactivity to lipoate and a conjugated form of lipoate in primary biliary cirrhosis. Gastroenterology 2003;125:1705-13.
111. Long SA, Quan C, Van de Water J, Nantz MH, Kurth MJ, Barsky D, et al. Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. J Immunol 2001;167:2956-63.
112. Kita H, Lian ZX, Van de Water J, He XS, Matsumura S, Kaplan M, et al. Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med 2002;195:113-23.
113. Reynoso-Paz S, Leung PS, Van De Water J, Tanaka A, Munoz S, Bass N, et al. Evidence for a locally driven mucosal response and the presence of mitochondrial antigens in saliva in primary biliary cirrhosis. Hepatology 2000;31:24-9.
114. Tanaka A, Nezu S, Uegaki S, Mikami M, Okuyama S, Kawamura N, et al. The clinical significance of IgA antimitochondrial antibodies in sera and saliva in primary biliary cirrhosis. Ann N Y Acad Sci 2007;1107:259-70.
115. Kisand KE, Kisand KV, Karvonen AL, Vuoristo M, Mattila J, Makinen J, et al. Antibodies to pyruvate dehydrogenase in primary biliary cirrhosis: correlation with histology. APMIS 1998;106:884-92.
116. James SP, Jones EA, Schafer DF, Hoofnagle JH, Varma RR, Strober W. Selective immunoglobulin A deficiency associated with primary biliary cirrhosis in a family with liver disease. Gastroenterology 1986;90:283-8.
117. Granito A, Muratori P, Quarneti C, Pappas G, Cicola R, Muratori L. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Rev Mol Diagn 2012;12:65-74.
118. Remmel T, Piirsoo A, Koiveer A, Remmel H, Uibo R, Salupere V. Clinical significance of different antinuclear antibodies patterns in the course of primary biliary cirrhosis. Hepatogastroenterology 1996;43:1135-40.
119. Shimoda S, Nakamura M, Ishibashi H, Kawano A, Kamihira T, Sakamoto N, et al. Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis. Gastroenterology 2003;124:1915-25.
120. Janka C, Selmi C, Gershwin ME, Will H, Sternsdorf T. Small ubiquitin-related modifiers: a novel and independent class of autoantigens in primary biliary cirrhosis. Hepatology 2005;41:609-16.
121. Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007;45:118-27.
122. Hu CJ, Zhang FC, Li YZ, Zhang X. Primary biliary cirrhosis: what do autoantibodies tell us? World J Gastroenterol 2010;16:3616-29.
123. Kikuchi K, Lian ZX, Kimura Y, Selmi C, Yang GX, Gordon SC, et al. Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis. J Autoimmun 2005;24:347-52.
124. Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev 2004;197:179-91.
125. Aranburu A, Ceccarelli S, Giorda E, Lasorella R, Ballatore G, Carsetti R. TLR ligation triggers somatic hypermutation in transitional B cells inducing the generation of IgM memory B cells. J Immunol 2010;185:7293-301.
126. Kurosaki T, Aiba Y, Kometani K, Moriyama S, Takahashi Y. Unique properties of memory B cells of different isotypes. Immunol Rev 2010;237:104-16.
127. Murata Y, Abe M, Hiasa Y, Azemoto N, Kumagi T, Furukawa S, et al. Liver/spleen volume ratio as a predictor of prognosis in primary biliary cirrhosis. J Gastroenterol 2008;43:632-6.
128. Terayama N, Makimoto KP, Kobayashi S, Nakanuma Y, Sasaki M, Saito K, et al. Pathology of the spleen in primary biliary cirrhosis: an autopsy study. Pathol Int 1994;44:753-8.
129. Kita H, Naidenko OV, Kronenberg M, Ansari AA, Rogers P, He XS, et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 2002;123:1031-43.
130. Mao TK, Lian ZX, Selmi C, Ichiki Y, Ashwood P, Ansari AA, et al. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology 2005;42:802-8.
131. Barak V, Selmi C, Schlesinger M, Blank M, Agmon-Levin N, Kalickman I, et al. Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. J Autoimmun 2009;33:178-82.
132. Allina J, Stanca CM, Garber J, Hu B, Sautes-Fridman C, Bach N, et al. Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. J Autoimmun 2008;30:238-45.
133. Ekdahl KN, Loof L, Nyberg A, Nilsson UR, Nilsson B. Defective Fc receptor-mediated clearance in patients with primary biliary cirrhosis. Gastroenterology 1991;101:1076-82.
134. Loof L, Hakansson L, Nyberg A, Venge P. Defective C3b receptor-mediated phagocytosis of neutrophils in patients with primary biliary cirrhosis. Scand J Gastroenterol 1987;22:1169-74.
135. Dienstag JL, Savarese AM, Cohen RB, Bhan AK. Circulating immune complexes in primary biliary cirrhosis: interactions with lymphoid cells. Clin Exp Immunol 1982;50:7-16.
136. Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, Mega JL, et al. Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet 2012;90:410-25.
137. Renz H, von Mutius E, Brandtzaeg P, Cookson WO, Autenrieth IB, Haller D. Gene-environment interactions in chronic inflammatory disease. Nat Immunol 2011;12:273-7.
138. Bock KW, Kohle C. The mammalian aryl hydrocarbon (Ah) receptor: from mediator of dioxin toxicity toward physiological functions in skin and liver. Biol Chem 2009;390:1225-35.
139. Wei HX, Chuang YH, Li B, Wei H, Sun R, Moritoki Y, et al. CD4+ CD25+ Foxp3+ regulatory T cells protect against T cell-mediated fulminant hepatitis in a TGF-beta-dependent manner in mice. J Immunol 2008;181:7221-9.
140. Oertelt S, Lian ZX, Cheng CM, Chuang YH, Padgett KA, He XS, et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 2006;177:1655-60.
141. Aoki CA, Borchers AT, Li M, Flavell RA, Bowlus CL, Ansari AA, et al. Transforming growth factor beta (TGF-beta) and autoimmunity. Autoimmun Rev 2005;4:450-9.
142. Moteki S, Leung PS, Coppel RL, Dickson ER, Kaplan MM, Munoz S, et al. Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies. Hepatology 1996;24:97-103.
143. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353:1261-73.